Core Viewpoint - The company Hims & Hers Health, Inc. (NYSE: HIMS) is perceived as undervalued by the market, which has led to a bullish outlook on its stock performance [1]. Group 1: Investment Strategy - The investment strategy involves a balanced portfolio of low-cost funds and individual stocks, with a focus on long-term holding of at least 10 years [1]. - The analyst emphasizes the importance of understanding market behavior beyond numerical valuations, viewing the market as a meeting point of demand and supply [1]. Group 2: Current Position and Performance - The analyst holds a position in HIMS valued at approximately $10,000, having previously realized a gain of over 50% on the original investment [3]. - The intention is to maintain the remaining position for the long term, with potential additions during market weaknesses [3].

Core Insights - The article emphasizes the importance of identifying deeply undervalued equities with long-term potential that are often overlooked by the market [1] Group 1: Investment Strategy - The focus is on managing investments since 1999, which provides a perspective across multiple market cycles [1] - The analyst has a background in Economics and is pursuing CFA certification, indicating a strong foundation in financial analysis [1] Group 2: Market Perspective - The article suggests that there are significant opportunities in the market for undervalued stocks that may not be recognized by the broader investment community [1]

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to start Q4, consider joining Out Fox The Street .Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in HIMS over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not r ...

Group 1 - The article discusses the potential for investing in undervalued stocks that are mispriced by the market as Q4 approaches [1] - It suggests that investors may consider joining a specific service to gain insights on these investment opportunities [1] Group 2 - There is a mention of a potential long position in HIMS, indicating a possible interest in this stock within the next 72 hours [2] - The article emphasizes that the opinions expressed are those of the author and not influenced by any compensation from companies mentioned [2] Group 3 - The information provided is intended for informational purposes only and does not constitute a solicitation to buy or sell securities [3] - It highlights the importance of conducting personal research or consulting a financial advisor before making investment decisions [3]

Key Points - NIO-SW (09866) rose over 4% as CEO Li Bin emphasized the necessity of achieving profitability in Q4 during an internal meeting on October 17 [1] - COSCO Shipping Energy (01138) increased over 4% due to successful capital increase enhancing future shipping capacity and strategic value in international shipping competition [1] - Datang New Energy (01798) fell over 4% despite a more than 10% increase in power generation in the first nine months, influenced by adjustments in VAT policies for wind power [1] - Laopuhuang Gold (06181) dropped over 6%, although it still recorded a cumulative increase of over 10% this month, with a price adjustment announcement set for October 26 [1] - Jitu Express-W (01519) rose over 3% as Q3 parcel volume exceeded market expectations, with anti-involution policies likely to restore company profits [1] - JD Health (06618) increased over 4% as institutions expect enhanced drug sales to benefit overall gross margin [1] - Derin Holdings (01709) rose over 3% after announcing plans to acquire 2,995 BM mining machines from Bitmain, strengthening its Bitcoin mining business [1] - Sanhua Intelligent Control (02050) increased over 6% after announcing an increase in the share repurchase price limit, with recent catalysts in the robotics sector [1] - Bilibili-W (09626) rose over 3% as Q3 advertising performance is expected to continue, with a new card game set to contribute additional revenue early next year [1] - Alibaba-W (09988) rose over 4% after partnering with Ant Group to acquire a 13-story commercial building in Causeway Bay for HKD 7.2 billion [2] US Market Highlights - CSX Transportation (CSX.US) rose 1.69% as CEO Steve Angel indicated a focus on strategic opportunities and reevaluating aspects of railroad operations [3] - Novo Nordisk (NVO.US) fell 3.07% and Eli Lilly (LLY.US) dropped 2.02% following Trump's comments on potential price reductions for the weight loss drug Ozempic [3] - American Lithium (LAC.US) fell 8.12% after JPMorgan downgraded its rating from "neutral" to "underweight," citing overvaluation concerns [3] - Ford Motor Company (F.US) rose 1.53% as the NHTSA announced a recall of nearly 625,000 vehicles due to safety issues [3] - ASE Technology Holding (ASX.US) continued to rise 1.11% with the expansion of its K18B advanced packaging plant expected to commence production in Q1 2028 [3] - NetEase (NTES.US) fell 0.26% after announcing the discontinuation of its mobile game "The Lord of the Rings: Rise to War" [3] - Oracle (ORCL.US) fell 6.93% as it projected a 35% gross margin for its AI infrastructure plans during the Oracle AI World conference [4] - Hims & Hers Health (HIMS.US) dropped 15.84% after launching affordable treatment options for perimenopausal and menopausal individuals [4] - Gold stocks generally declined, with Harmony Gold (HMY.US) down 8.86% and Kinross Gold (KGC.US) down 8.99%, amid a significant drop in spot gold prices [4]

Market Overview - Wall Street experienced a decline from record highs due to renewed tariff threats from President Trump against China, impacting investor sentiment and leading to a selloff in export-sensitive and financial stocks [2] - Concerns regarding regional bank credit, particularly bad loans reported by Zions Bancorp and Western Alliance Bancorp, contributed to the market downturn [2][10] - The Federal Reserve faced pressure as Trump's rhetoric towards Chair Jerome Powell raised concerns about political interference in monetary policy, while uncertainty over the U.S. government shutdown affected economic outlooks [3] Bullish Stocks - Stellantis N.V. announced a $13 billion investment over four years to expand its U.S. manufacturing footprint by 50%, which resulted in a surge in its stock price [5] - Papa John's International shares rose following a new takeover offer from Apollo Global Management at $64 per share, although the deal's completion remains uncertain [6] - Oklo Inc. saw its stock soar nearly 700% year-to-date as it aims to deploy micro-nuclear reactors for U.S. military bases under the Pentagon's Project Janus initiative, despite facing regulatory challenges and having no commercial revenue [7] Bearish Stocks - U.S. semiconductor stocks, including NVIDIA, Micron, and Intel, fell sharply due to escalating trade tensions with China, exacerbated by Micron's exit from China's data center market following a ban on its products [8] - Shares of Eli Lilly, Novo Nordisk, and Hims & Hers Health declined after President Trump indicated that prices for "fat-loss drugs" would decrease significantly, leading to a selloff in GLP-1 therapy manufacturers [9] - Regional bank stocks, particularly Zions Bancorp and Western Alliance Bancorp, experienced their worst drop since April, with Zions disclosing a $60 million provision for troubled loans and Western Alliance facing a lawsuit for alleged fraud [10][11]

Core Viewpoint - The recent statements from former President Trump regarding the pricing of GLP-1 weight loss drugs have led to a significant decline in stock prices for companies like Eli Lilly and Hims & Hers Health, indicating potential pressure on drug pricing in the U.S. market [1][2]. Group 1: Market Impact - Eli Lilly's stock fell approximately 2%, while Hims & Hers Health experienced a more substantial drop of over 15% following Trump's comments [1]. - The U.S. government aims to reduce the price of popular GLP-1 drugs to $150 per month, significantly lower than current prices that can exceed $1,000 [1][2]. Group 2: Government Negotiations - The Centers for Medicare & Medicaid Services (CMS) director clarified that no agreements have been reached with pharmaceutical companies regarding GLP-1 pricing, despite ongoing negotiations [1]. - Eli Lilly and Novo Nordisk are among the 17 major pharmaceutical companies that received letters from the Trump administration requesting alignment of U.S. drug prices with those in other developed countries [1]. Group 3: Market Dynamics - A recent survey by the Kaiser Family Foundation revealed that only about 20% of large employers offer benefits for weight loss medications, with two-thirds reporting significant increases in prescription costs [2]. - Eli Lilly and Novo Nordisk are currently offering discounted versions of their drugs at around $500 per month, while Hims & Hers provides compounded versions priced between $130 and $200 [2]. - If the government successfully reduces the cash price of drugs like Zepbound and Wegovy to $150, it would directly compete with the current pricing of compounded medications, potentially disrupting the cash market landscape [2].

Core Insights - Hims & Hers Health Inc has announced its expansion into menopause-related treatments, targeting a large and underserved market [1] - The initial positive market reaction is beginning to fade, indicating potential volatility in stock performance [1] Company Summary - Hims & Hers Health Inc (NYSE: HIMS) is focusing on menopause-related treatments, which represents a significant opportunity within the healthcare sector [1] - The company is entering a market that has been largely neglected, suggesting potential for growth and increased revenue streams [1] Industry Summary - The menopause treatment market is characterized as large and underserved, highlighting a gap in existing healthcare offerings [1] - The expansion into this area may position Hims & Hers Health Inc favorably against competitors who have not yet addressed this demographic [1]

Core Viewpoint - Hims&Hers Health experienced a significant stock price fluctuation, with a 16% increase followed by a more than 10% decline, resulting in a total drop of 15% over two days, erasing previous gains [1] Company Developments - The company has launched an affordable treatment plan for individuals in perimenopause and menopause, expanding its business into the hormone replacement therapy sector [1] - Hims&Hers anticipates that this new specialized service will help its "Hers" division achieve an annual revenue exceeding $1 billion next year [1]

Core Insights - Hims & Hers Health, Inc. (HIMS) experienced a decline of 5.75% in its stock price, underperforming compared to the S&P 500's loss of 0.63% [1] - The company has shown a significant increase of 24.65% in its stock price over the past month, outperforming the Medical sector and the S&P 500 [1] Earnings Forecast - The upcoming earnings report is scheduled for November 3, 2025, with an expected EPS of $0.09, indicating a 50% increase from the same quarter last year [2] - Revenue is projected to reach $581.61 million, reflecting a 44.84% rise compared to the equivalent quarter last year [2] Annual Estimates - For the entire year, the Zacks Consensus Estimates predict earnings of $0.6 per share and revenue of $2.35 billion, representing increases of 122.22% and 59.03% respectively from the previous year [3] Analyst Estimates - Recent adjustments to analyst estimates for Hims & Hers Health, Inc. are crucial as they reflect short-term business trends and analysts' confidence in the company's performance [4] Zacks Rank and Performance - The Zacks Rank system currently rates Hims & Hers Health, Inc. at 4 (Sell), with a recent decline of 0.28% in the consensus EPS estimate [6] - Historically, stocks rated 1 (Strong Buy) have delivered an average annual return of +25% since 1988 [6] Valuation Metrics - Hims & Hers Health, Inc. has a Forward P/E ratio of 105.22, significantly higher than the industry average of 40.64, indicating a premium valuation [7] - The company also has a PEG ratio of 4.29, compared to the industry average of 3.33, suggesting higher anticipated earnings growth relative to its price [8] Industry Context - The Medical Info Systems industry, to which Hims & Hers belongs, has a Zacks Industry Rank of 93, placing it in the top 38% of over 250 industries [8] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [9]